RenovoRx Inc., a company listed on NASDAQ under the ticker symbol RNXT, has released an investor presentation detailing its latest advancements. The company is developing combination therapies utilizing its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform. This includes the RenovoCath device, which has received FDA Orphan Drug Designation for its combination with the drug Gemcitabine in treating pancreatic and bile duct cancers. RenovoRx has initiated the commercialization of the FDA-cleared RenovoCath, with revenues in the first half of 2025 surpassing expectations. The company is advancing a pivotal Phase III TIGeR-PaC study for treating locally advanced pancreatic cancer, observing increased overall survival and progression-free survival, and a 65% reduction in adverse effects in the first interim analysis. The study's completion is anticipated by late 2025 or early 2026. RenovoRx is pursuing a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device. The company is led by an experienced leadership team and board of directors with expertise in clinical development and commercial execution in pharma, medical device, and combination therapy companies. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.